TapewireFind a company

person · Reporting owner

Doebele Robert

Disclosed activity across 2 companies

Tapewire entity
68772
SEC CIK
0001856681

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Boundless Bio, Inc.BOLD · Entity 7063Chief Medical OfficerJanuary 23, 2026January 26, 2026
Rain Oncology Inc.RAIN · Entity 94695See RemarksJanuary 26, 2024January 26, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Boundless Bio, Inc.

Report date January 23, 2026 · Filed January 26, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.26 · Expires 2036-01-22Direct230,000 Reported balance After 2026-01-23 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-01-23 · Grant · Acquired 230,000 · Balance 230,000

F1: The vesting commencement date is January 1, 2026. The stock option vests in 48 substantially equal monthly installments. Accordingly, 1/48th of this stock option vests on February 1, 2026, and monthly thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: The vesting commencement date is January 1, 2026. The stock option vests in 48 substantially equal monthly installments. Accordingly, 1/48th of this stock option vests on February 1, 2026, and monthly thereafter.

Rain Oncology Inc.

Report date January 26, 2024 · Filed January 26, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common Stock, par value $0.001 per shareSEC Table I · non-derivativeDirect0 Reported balance After 2024-01-26 transaction · row 1
1 source row

Row 1 · 2024-01-26 · Other · Disposed 476,827 · Balance 0

F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $1.16 in cash without interest, plus (ii) one contingent value right.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.59Direct0 Reported balance After 2024-01-26 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2024-01-26 · Disposition to issuer · Disposed 11,119 · Balance 0

F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.00Direct0 Reported balance After 2024-01-26 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2024-01-26 · Disposition to issuer · Disposed 90,620 · Balance 0

F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.01Direct0 Reported balance After 2024-01-26 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2024-01-26 · Disposition to issuer · Disposed 12,358 · Balance 0

F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.95Direct0 Reported balance After 2024-01-26 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2024-01-26 · Disposition to issuer · Disposed 5,000 · Balance 0

F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.95Direct0 Reported balance After 2024-01-26 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2024-01-26 · Disposition to issuer · Disposed 13,890 · Balance 0

F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.59Direct0 Reported balance After 2024-01-26 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2024-01-26 · Disposition to issuer · Disposed 112,206 · Balance 0

F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.95Direct0 Reported balance After 2024-01-26 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2024-01-26 · Disposition to issuer · Disposed 9,260 · Balance 0

F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.21Direct0 Reported balance After 2024-01-26 transaction · row 9 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 9 · 2024-01-26 · Disposition to issuer · Disposed 99,400 · Balance 0

F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.21Direct0 Reported balance After 2024-01-26 transaction · row 10 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 10 · 2024-01-26 · Disposition to issuer · Disposed 49,700 · Balance 0

F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.13Direct0 Reported balance After 2024-01-26 transaction · row 11 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 11 · 2024-01-26 · Disposition to issuer · Disposed 9,260 · Balance 0

F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.00Direct0 Reported balance After 2024-01-26 transaction · row 12 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 12 · 2024-01-26 · Disposition to issuer · Disposed 1,981 · Balance 0

F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.01Direct0 Reported balance After 2024-01-26 transaction · row 13 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 13 · 2024-01-26 · Disposition to issuer · Disposed 59,642 · Balance 0

F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $1.16 in cash without interest, plus (ii) one contingent value right.

F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
January 23, 2026 Filed Jan 26, 2026 12:00 UTC Boundless Bio, Inc. BOLD · Entity 7063 GrantStock Option (right to buy) · Derivative 230,000 $0.00 Strike: $1.26 $0.00
Disclosure

SEC source: 0001193125-26-021656 · ownership.xml · derivative · entry 1

Doebele Robert · CIK 0001856681 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 230,000

Underlying: Common Stock · 230,000 shares

Expires 2036-01-22

F1 · derivative.exercise_date: The vesting commencement date is January 1, 2026. The stock option vests in 48 substantially equal monthly installments. Accordingly, 1/48th of this stock option vests on February 1, 2026, and monthly thereafter.

Read SEC document
February 03, 2025 Filed Feb 3, 2025 23:38 UTC Boundless Bio, Inc. BOLD · Entity 7063 GrantStock Option · Derivative 180,000 $0.00 Strike: $2.23 $0.00
Disclosure

SEC source: 0000950170-25-012568 · ownership.xml · derivative · entry 1

Doebele Robert · CIK 0001856681 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Common Stock · 180,000 shares

Expires 2035-02-03

F1 · derivative.exercise_date: The option shall vest over a period of four years, with 25% of the shares subject to the option vesting on February 3, 2026, and the remaining shares subject to the option vesting in 36 equal monthly installments thereafter, subject to continued employment or service to the issuer on each such vesting date.

Read SEC document
January 26, 2024 Filed Jan 26, 2024 16:36 UTC Rain Oncology Inc. RAIN · Entity 94695 Disposition to issuerStock Option (Right to Buy) · Derivative 59,642 Not disclosed Strike: $12.01 Not disclosed
Disclosure

SEC source: 0001999371-24-000958 · ownership.xml · derivative · entry 13

Doebele Robert · CIK 0001856681 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 59,642 shares

Expires not disclosed

F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

Read SEC document
January 26, 2024 Filed Jan 26, 2024 16:36 UTC Rain Oncology Inc. RAIN · Entity 94695 Disposition to issuerStock Option (Right to Buy) · Derivative 1,981 Not disclosed Strike: $4.00 Not disclosed
Disclosure

SEC source: 0001999371-24-000958 · ownership.xml · derivative · entry 12

Doebele Robert · CIK 0001856681 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,981 shares

Expires not disclosed

F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

Read SEC document
January 26, 2024 Filed Jan 26, 2024 16:36 UTC Rain Oncology Inc. RAIN · Entity 94695 Disposition to issuerStock Option (Right to Buy) · Derivative 9,260 Not disclosed Strike: $3.13 Not disclosed
Disclosure

SEC source: 0001999371-24-000958 · ownership.xml · derivative · entry 11

Doebele Robert · CIK 0001856681 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,260 shares

Expires not disclosed

F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

Read SEC document
January 26, 2024 Filed Jan 26, 2024 16:36 UTC Rain Oncology Inc. RAIN · Entity 94695 Disposition to issuerStock Option (Right to Buy) · Derivative 49,700 Not disclosed Strike: $1.21 Not disclosed
Disclosure

SEC source: 0001999371-24-000958 · ownership.xml · derivative · entry 10

Doebele Robert · CIK 0001856681 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 49,700 shares

Expires not disclosed

F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

Read SEC document
January 26, 2024 Filed Jan 26, 2024 16:36 UTC Rain Oncology Inc. RAIN · Entity 94695 Disposition to issuerStock Option (Right to Buy) · Derivative 99,400 Not disclosed Strike: $1.21 Not disclosed
Disclosure

SEC source: 0001999371-24-000958 · ownership.xml · derivative · entry 9

Doebele Robert · CIK 0001856681 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 99,400 shares

Expires not disclosed

F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

Read SEC document
January 26, 2024 Filed Jan 26, 2024 16:36 UTC Rain Oncology Inc. RAIN · Entity 94695 Disposition to issuerStock Option (Right to Buy) · Derivative 9,260 Not disclosed Strike: $3.95 Not disclosed
Disclosure

SEC source: 0001999371-24-000958 · ownership.xml · derivative · entry 8

Doebele Robert · CIK 0001856681 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,260 shares

Expires not disclosed

F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

Read SEC document
January 26, 2024 Filed Jan 26, 2024 16:36 UTC Rain Oncology Inc. RAIN · Entity 94695 Disposition to issuerStock Option (Right to Buy) · Derivative 112,206 Not disclosed Strike: $9.59 Not disclosed
Disclosure

SEC source: 0001999371-24-000958 · ownership.xml · derivative · entry 7

Doebele Robert · CIK 0001856681 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 112,206 shares

Expires not disclosed

F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

Read SEC document
January 26, 2024 Filed Jan 26, 2024 16:36 UTC Rain Oncology Inc. RAIN · Entity 94695 Disposition to issuerStock Option (Right to Buy) · Derivative 13,890 Not disclosed Strike: $3.95 Not disclosed
Disclosure

SEC source: 0001999371-24-000958 · ownership.xml · derivative · entry 6

Doebele Robert · CIK 0001856681 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,890 shares

Expires not disclosed

F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

Read SEC document
January 26, 2024 Filed Jan 26, 2024 16:36 UTC Rain Oncology Inc. RAIN · Entity 94695 Disposition to issuerStock Option (Right to Buy) · Derivative 5,000 Not disclosed Strike: $3.95 Not disclosed
Disclosure

SEC source: 0001999371-24-000958 · ownership.xml · derivative · entry 5

Doebele Robert · CIK 0001856681 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires not disclosed

F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

Read SEC document
January 26, 2024 Filed Jan 26, 2024 16:36 UTC Rain Oncology Inc. RAIN · Entity 94695 Disposition to issuerStock Option (Right to Buy) · Derivative 12,358 Not disclosed Strike: $12.01 Not disclosed
Disclosure

SEC source: 0001999371-24-000958 · ownership.xml · derivative · entry 4

Doebele Robert · CIK 0001856681 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,358 shares

Expires not disclosed

F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

Read SEC document
January 26, 2024 Filed Jan 26, 2024 16:36 UTC Rain Oncology Inc. RAIN · Entity 94695 Disposition to issuerStock Option (Right to Buy) · Derivative 90,620 Not disclosed Strike: $4.00 Not disclosed
Disclosure

SEC source: 0001999371-24-000958 · ownership.xml · derivative · entry 3

Doebele Robert · CIK 0001856681 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 90,620 shares

Expires not disclosed

F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

Read SEC document
January 26, 2024 Filed Jan 26, 2024 16:36 UTC Rain Oncology Inc. RAIN · Entity 94695 Disposition to issuerStock Option (Right to Buy) · Derivative 11,119 Not disclosed Strike: $9.59 Not disclosed
Disclosure

SEC source: 0001999371-24-000958 · ownership.xml · derivative · entry 2

Doebele Robert · CIK 0001856681 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,119 shares

Expires not disclosed

F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.

Read SEC document
January 26, 2024 Filed Jan 26, 2024 16:36 UTC Rain Oncology Inc. RAIN · Entity 94695 OtherCommon Stock, par value $0.001 per share 476,827 Not disclosed Not disclosed
Disclosure

SEC source: 0001999371-24-000958 · ownership.xml · nonDerivative · entry 1

Doebele Robert · CIK 0001856681 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $1.16 in cash without interest, plus (ii) one contingent value right.

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $1.16 in cash without interest, plus (ii) one contingent value right.

F1 · acquired: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $1.16 in cash without interest, plus (ii) one contingent value right.

Read SEC document
August 09, 2023 Filed Aug 11, 2023 21:16 UTC Rain Oncology Inc. RAIN · Entity 94695 GrantStock Option (Right to Buy) · Derivative 49,700 $0.00 Strike: $1.21 $0.00
Disclosure

SEC source: 0001104659-23-090705 · tm2323614-9_4seq1.xml · derivative · entry 2

Doebele Robert · CIK 0001856681 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,700

Underlying: Common Stock · 49,700 shares

Expires 2033-08-09

F2 · derivative.exercise_date: This option represents a right to purchase a total of 49,700 shares of the Issuer's common stock, which will vest in equal installments on May 9, 2024 and February 9, 2025, subject to the achievement of certain corporate goals and the Reporting Person's continued service to the Issuer.

Read SEC document
August 09, 2023 Filed Aug 11, 2023 21:16 UTC Rain Oncology Inc. RAIN · Entity 94695 GrantStock Option (Right to Buy) · Derivative 99,400 $0.00 Strike: $1.21 $0.00
Disclosure

SEC source: 0001104659-23-090705 · tm2323614-9_4seq1.xml · derivative · entry 1

Doebele Robert · CIK 0001856681 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,400

Underlying: Common Stock · 99,400 shares

Expires 2033-08-09

F1 · derivative.exercise_date: This option represents a right to purchase a total of 99,400 shares of the Issuer's common stock, which will vest in equal installments on May 9, 2024 and February 9, 2025, subject to the Reporting Person's continued service to the Issuer.

Read SEC document
February 15, 2023 Filed Feb 17, 2023 18:18 UTC Rain Oncology Inc. RAIN · Entity 94695 GrantStock Option (Right to Buy) · Derivative 123,325 $0.00 Strike: $9.30 $0.00
Disclosure

SEC source: 0001104659-23-023387 · tm237300-2_4seq1.xml · derivative · entry 1

Doebele Robert · CIK 0001856681 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 123,325

Underlying: Common Stock · 123,325 shares

Expires 2033-02-15

F1 · derivative.exercise_date: This option represents a right to purchase a total of 123,325 shares of the Issuer's common stock, one quarter of which will vest on February 15, 2024, with the remaining three quarters vesting in equal monthly installments through February 15, 2027, subject to the Reporting Person's continued service to the Issuer.

Read SEC document
July 06, 2022 Filed Jul 7, 2022 18:02 UTC Rain Oncology Inc. RAIN · Entity 94695 Exercise / conversionStock Option (Right to Buy) · Derivative 3,890 $0.00 Strike: $3.95 $0.00
Disclosure

SEC source: 0000899243-22-025741 · doc4.xml · derivative · entry 2

Doebele Robert · CIK 0001856681 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 3,890 shares

Expires 2029-03-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option represents a right to purchase a total of 13,890 shares of Issuer's common stock, which is vested in full.

Read SEC document
July 06, 2022 Filed Jul 7, 2022 18:02 UTC Rain Oncology Inc. RAIN · Entity 94695 Exercise / conversionCommon Stock 3,890 $3.95 $15,365.50
Disclosure

SEC source: 0000899243-22-025741 · doc4.xml · nonDerivative · entry 1

Doebele Robert · CIK 0001856681 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 476,827

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
April 13, 2022 Filed Apr 15, 2022 16:30 UTC Rain Oncology Inc. RAIN · Entity 94695 Exercise / conversionStock Option (Right to Buy) · Derivative 3,000 $0.00 Strike: $3.95 $0.00
Disclosure

SEC source: 0000899243-22-014886 · doc4.xml · derivative · entry 2

Doebele Robert · CIK 0001856681 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,890

Underlying: Common Stock · 3,000 shares

Expires 2029-03-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option represents a right to purchase a total of 13,890 shares of Issuer's common stock, which is vested in full.

Read SEC document
April 13, 2022 Filed Apr 15, 2022 16:30 UTC Rain Oncology Inc. RAIN · Entity 94695 Exercise / conversionCommon Stock 3,000 $3.95 $11,850.00
Disclosure

SEC source: 0000899243-22-014886 · doc4.xml · nonDerivative · entry 1

Doebele Robert · CIK 0001856681 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 472,937

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 31, 2022 Filed Apr 4, 2022 16:15 UTC Rain Oncology Inc. RAIN · Entity 94695 Exercise / conversionStock Option (Right to Buy) · Derivative 2,000 $0.00 Strike: $3.95 $0.00
Disclosure

SEC source: 0000899243-22-013322 · doc4.xml · derivative · entry 2

Doebele Robert · CIK 0001856681 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,890

Underlying: Common Stock · 2,000 shares

Expires 2029-03-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option represents a right to purchase a total of 13,890 shares of Issuer's common stock, which is vested in full.

Read SEC document
March 31, 2022 Filed Apr 4, 2022 16:15 UTC Rain Oncology Inc. RAIN · Entity 94695 Exercise / conversionCommon Stock 2,000 $3.95 $7,900.00
Disclosure

SEC source: 0000899243-22-013322 · doc4.xml · nonDerivative · entry 1

Doebele Robert · CIK 0001856681 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 469,937

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 07, 2022 Filed Feb 4, 2022 16:35 UTC Rain Oncology Inc. RAIN · Entity 94695 GrantStock Option (Right to Buy) · Derivative 72,000 $0.00 Strike: $12.01 $0.00
Disclosure

SEC source: 0000899243-22-004834 · doc4.xml · derivative · entry 1

Doebele Robert · CIK 0001856681 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,000

Underlying: Common Stock · 72,000 shares

Expires 2032-01-07

F1 · derivative.exercise_date: This option represents a right to purchase a total of 72,000 shares of the Issuer's common stock, one quarter of which will vest on January 7, 2023, with the remaining three quarters vesting in equal monthly installments through January 7, 2026, subject to the Reporting Person's continued service to the Issuer.

Read SEC document
April 27, 2021 Filed Apr 27, 2021 17:04 UTC Rain Oncology Inc. RAIN · Entity 94695 ConversionSeries A Preferred Stock · Derivative 5,327 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-017112 · doc4.xml · derivative · entry 2

Doebele Robert · CIK 0001856681 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,932 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-1.0799 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · derivative.exercise_date: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-1.0799 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F1 · derivative.expiration_date: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-1.0799 basis upon the closing of the Issuer's initial public offering and had no expiration date.

Read SEC document
April 27, 2021 Filed Apr 27, 2021 17:04 UTC Rain Oncology Inc. RAIN · Entity 94695 ConversionCommon Stock 4,932 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-21-017112 · doc4.xml · nonDerivative · entry 1

Doebele Robert · CIK 0001856681 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 467,937

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-1.0799 basis upon the closing of the Issuer's initial public offering and had no expiration date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.